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Abstract.
Background: Early onset dementias have variable clinical presentations and are often difficult to diagnose. We established a
family pedigree that demonstrated consistent recurrence of very early onset dementia in successive generations.
Objective andMethod: In order to refine the diagnosis in this family, we sequenced the exomes of two affected family members
and relied on discrete filtering to identify disease genes and the corresponding causal variants.
Results: Among the 720 nonsynonymous single nucleotide polymorphisms (SNPs) shared by two affected members, we found
a C to T transition that gives rise to a Thr147Ile missense substitution in the presenilin 1 (PS1) protein. The presence of this
same mutation in a French early-onset Alzheimer’s disease family, other affected members of the family, and the predicted
high pathogenicity of the substitution strongly suggest that it is the causal variant. In addition to exceptionally young age of
onset, we also observed significant limb spasticity and early loss of speech, concurrent with progression of dementia in affected
family members. These findings extend the clinical presentation associated with the Thr147Ile variant. Lastly, one member with
the Thr147Ile variant was treated with the PKC epsilon activator, bryostatin, in a compassionate use trial after successful FDA
review. Initial improvements with this treatment were unexpectedly clear, including return of some speech, increased attentional
focus, ability to swallow, and some apparent decrease in limb spasticity.
Conclusions: Our findings confirm the role of the PS1 Thr147Ile substitution in Alzheimer’s disease and expand the clinical
phenotype to include expressive aphasia and very early onset of dementia.
Keywords: Bryostatin, early-onset Alzheimer’s disease, expressive aphasia, PSEN1, whole exome sequencing
1Goran Boskovic PhD passed away unexpectedly on July 14,
2013.
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INTRODUCTION
Scores of disease processes may ultimately lead
to dementia, but there are four major primary dis-
orders with dementia as their main clinical feature:
Alzheimer’s disease (AD), frontotemporal lobe degen-
eration (FTLD), cerebrovascular disease, and dementia
with Lewy bodies [1, 2]. Diagnosis of the disease
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type is clinically challenging because of difficulty in
the assessment of memory and cognitive impairment
(especially in the early stages) and incomplete knowl-
edge of clinical phenotypes [2]. Even within the set
of PSEN1 variants that cause early-onset Alzheimer’s
disease (EOAD), there is substantial clinical hetero-
geneity [3–6]. Given that many EOAD and FTLD
dementias are Mendelian disorders with known causal
genes [7–11], diagnosis could be improved by system-
atic identification of causal variants.
We describe two members of an extended family
with early-onset dementia (Fig. 1). The presence of
multiple affected family members in each generation
suggested that the disease was an autosomal dominant
form of AD. Both of our patients had advanced disease.
One had only limited information available about her
history and the second had certain atypical findings, so
that a diagnosis of AD on a purely clinical basis was
not warranted.
Most cases of EOAD are caused by mutations in
either APP (13–16%), PSEN1 (18–50%), or PSEN2
(rare) [12, 13]. Since variants in known causal loci
only explain a fraction of early-onset dementias, we
performed whole exome sequencing with discrete fil-
tering on two affected family members in order to
identify causal variants and make a more accurate diag-
nosis. We found that both patients carried a known
rare variant in PS1 (Thr147Ile) and that heterozygos-
ity for APOE 4 in both cases may have decreased
the age of onset. In addition, we add exceptionally
early age of onset and specifically expressive aphasia
to the spectrum of clinical features of patients with the
Thr147Ile variant. Extensive pre-clinical research with
AD-transgenic mice [14] and clinical data that included
autopsy-confirmed diagnostic specificity of the protein
kinase C (PKC) pathway [15, 16] provided a ratio-
nale for an FDA approval for a Phase 2a clinical trial
with the highly potent PKC activator, bryostatin. On
that basis we undertook a compassionate use trial with
bryostatin for a family member with advance symp-
toms of AD. This trial yielded some promising initial
results of therapeutic efficacy for this drug.
MATERIALS AND METHODS
Description of family and consent process
We were made aware of a multigenerational family
in which affected members developed severe dementia
beginning at an early age. The family had been brought
to the attention of the Blanchette Rockefeller Neuro-
sciences Institute by a concerned unaffected family
member who was seeking information about treatment
options. Beginning in May 2011, a study of the family
was initiated following approval of a study protocol
by the Marshall University Institutional Review Board
(IRBNet ID #247818-6). The five-generation pedigree
constructed based on information provided by unaf-
fected family members and review of available family
history documents revealed an autosomal dominant
inheritance pattern (Fig. 1). At that time, five affected
family members were still alive; IV-2, IV-12, and IV-
18 were 37 years old, IV-16 was 38 years old, and
III-29 was 57 years old. All affected members exhib-
ited the earliest signs of dementia when they were in
their mid to late 20 s. Within weeks of completion of the
pedigree, patient IV-16 and patient IV-12 died. By med-
ical power of attorney, guardians of the 57-year-old
patient (III-29) and her 37-year-old daughter (IV-18)
consented to further study; the remaining patient (IV-
2) declined to participate. The two consented patients
underwent a history and physical examination prior
to genomic analysis. Both patients were located in a
remote rural area and neither was able to be transported
to a facility with full examination capability.
Case one (Patient IV-18)
Patient IV-18, a 37-year-old woman, was healthy
and active until 10 years prior to this examination. She
had completed three years of college, had no learning
difficulties, and had been employed as a bank teller.
The first symptom noted by her husband was that,
whereas she had always been athletic and had partic-
ipated in many organized sports, she was unable to
learn how to ski when she attempted it for the first
time at age 27. Since then, there had been a steady
decline in her motor skills as well as her executive
and other cognitive functions. She frequently mis-
placed items and was repetitive. Her husband reported
that her speech had become increasingly impaired. He
described her as being generally unable to express
herself and becoming frustrated because of that. He
also indicated that she was more fluent when she
was agitated and could still say a few expletives. She
had no reported hallucinations or delusions, but had
demonstrated misidentification of her own face in a
mirror. She was non-ambulatory by the time of the
first examination and had significant muscle tone in all
limbs which had progressed in spite of active physical
therapy and medication for muscle spasms. She had
increasingly frequent episodes of dysphagia, and had
a percutaneous gastrostomy tube placed for feeding.
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Her past history included no depression, no head
injury, and no previous intracerebral pathology or
seizure history. In a neurocognitive examination com-
pleted 2 years and 9 months before this examination, a
diagnosis of dementia was given based on findings of
severe global cognitive deficits. Specific findings of the
neuropsychological examination included markedly
slowed general cognitive efficiency, visual scanning,
and motor response. Her spontaneous speech at that
time was generally fluent with no word-finding prob-
lems though it was of limited output. Her auditory
attention was severely impaired, as was her visual
memory and verbal abstraction.
On the current physical examination, she was in
no acute distress. The examination was normal except
for the following observations. She was alert but non-
verbal. She was responsive to voice and touch in that
she would turn her head or eyes toward the examiner.
Frequent myoclonic jerks and generalized increased
motor tone of all limbs were noted; flexion contractures
of a minimal degree were present in all extremities.
Cognitive testing was not possible due to her non-
verbal state.
Case two (Patient III-29)
Patient III-29, mother of IV-18, was a 57-year-old
woman who had been confined to nursing homes since
1992 when she was 38 years old. No medical records
are available from any time before she was admitted
to her current nursing facility in 2000. The earliest
symptoms were unknown. Based on information in
her current nursing home medical record, patient III-
29 was known to have been having seizures by age
35, and evidence of cognitive impairment was present
several years before that. By the time of admission to
her current facility (when she was 46 years old), she
was non-verbal and bed-confined. Since 2000, she had
frequent seizures but otherwise was medically stable.
On examination, she was non-verbal. Her eyes
would open after several verbal and tactile stimula-
tions. No purposeful motor movements were seen and
no visual tracking occurred. She had a percutaneous
gastrostomy tube in place, and had widespread severe
flexion contractures in all extremities.
Summary of clinical findings
Patient III-29 was at such an extreme stage that her
clinical findings were indicative of end-stage disease
and therefore not instructive in delineation of the rare
mutation she suffered. Patient IV-18, however, had sev-
eral unusual features in her presentation. She had fairly
intact awareness of her surroundings, in contrast to the
bewilderment so often seen in AD patients. Addition-
ally she had prominent myoclonic jerks and increased
muscle tone, which are infrequently seen at her stage
of disease and which seldom involve all extremities.
Published phenotype descriptions are almost exclu-
sively characterized as spastic paraparesis (reviewed
by Larner and Doran [3]).
Finally, her speech abnormality was atypical as well,
more closely resembling a classic expressive aphasia
than the variant aphasias usually described in AD. The
latter pathology frequently leads to speech patterns
consistent with the logopenic variant of primary pro-
gressive aphasia, with single word retrieval issues and
impaired repetition of words or phrases [17], whereas
these abnormalities were specifically denied in her his-
tory and not seen on earlier neuropsychological testing.
Whole exome sequencing and discrete filtering
Blood (15 ml) was obtained by venipuncture from
each patient. Genomic DNA was extracted from white
blood cells of both patients using a Qiagen Blood
and Cell Culture DNA Maxi Kit. Whole exome
libraries were constructed using Illumina TruSeq DNA
Sample Prep and TruSeq Exome Enrichment Kits
and sequenced in a 2 × 100 bp paired end strategy
on an Illumina HiSeq1000 in the Marshall Univer-
sity Genomics Core Facility. Approximately 12,000
megabases were sequenced in each patient. Eighty-
five percent of reads passing a Casava chastity filter
uniquely aligned to the hg19 reference human genome.
Aligned reads were assembled by location (pileups)
using SamTools v0.1.18. Exons were identified from
UCSC’s refFlat table. Coverage statistics were com-
puted as the average pileup over locations in exons.
Average exonic read depth was 130x and 139x for
III-29 and IV-18, respectively.
Reads were aligned to hg19 (GRCh37) using
Elandv2 (Illumina, San Diego CA). Small variants
(SNPs and indels) were identified using CASAVA
v1.8.2 (Illumina) for each sample. SNPs were filtered
under an autosomal dominant (AutoDom) and an auto-
somal recessive (AutoRec) model. For the AutoDom
model, SNPs that were present in either heterozygous
or homozygous form in both patients were collated.
For the AutoRec model, SNPs that were present in
both patients in homozygous form were collated. In
both models, SNPs were annotated using the UCSC
Genome Browser database (refFlat table) and clas-
sified as extragenic, intronic, splice-site, TATA box,
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coding synonymous, missense, or nonsense. Extra-
genic, intronic, and exonic synonymous SNPs were
filtered out. Finally, SNPs listed in the NCBI dbSNP
database that had high minor allele frequencies (>0.05
for AutoDom or >0.25 for AutoRec) were filtered out.
SNPs that passed filter are shown in Supplementary
Table 1. Indels were classified as coding if the inserted
or deleted sequence overlapped a coding sequence.
Coding indels were classified as frameshifting if the
number of coding bases changed by a number not
a multiple of three. Effects of coding variants were
evaluated using Polyphen-2 software [18].
RESULTS
Identification of potential causal variants through
discrete filtering of whole exome data
We used a discrete filtering scheme on whole exome
variant data to identify potential candidate single
nucleotide variants (SNVs) in patients III-29 and IV-
18. By comparison to the hg19 reference genome,
we initially identified ∼2 million SNVs/patient (III-
29:2,285,481 SNVs; IV-18:2,318,828 SNVs); 640,671
SNVs were common to both family members. Under
an autosomal dominant scheme, we restricted the pool
to SNVs whose minor allele frequency was less than
5% or were not listed in dbSNP database. We then
filtered for SNVs that either resulted in a missense
or nonsense mutation or were located in a splice site.
Using this strategy, we obtained 720 nonsynonymous
SNVs distributed over 582 different genes. Polyphen-
2 analysis indicated that 432 were benign, 125 were
“possibly damaging”, 161 were “probably damaging”
and 2 were “unknown” (Supplementary Table 1). In
this set, we found a C−→T transition (rs63750907)
that causes a Thr147Ile missense substitution in exon
5 of the 467 amino acid PS1 protein. This substi-
tution is predicted to be “Probably Damaging” with
a score of 1.000 by Polyphen-2 analysis (sensitivity:
0.00; specificity: 1.00). The same variant was found in
four patients in a French family with autosomal domi-
nant EOAD [19] and in two affected cousins of IV-18
(IV-1 and IV-2) by diagnostic testing. Both cousins
were diagnosed with dementia in their late twenties.
Patient IV-1 died at age 36; patient IV-2 was 37 years
of age at the time of pedigree construction.
We searched for causal and risk variants in other
known dementia genes. No coding variants were found
in either III-29 or IV-18 in APP, GRN, MAPT, or
PSEN2. Neither the TREM2 Arg47His nor the PLD3
Val232Met substitution was present in either patient.
We found a common coding variant (rs1799990,
MAF = 0.26) in the PRPN gene in patient III-29 only.
This variant results in a Met129Val missense sub-
stitution which is a risk factor for Creutzfeldt-Jakob
disease.
Under the autosomal recessive model, we found
159 nonsynonymous SNPs distributed over 131 genes.
Polyphen-2 identified 10 of these as possibly damaging
and 5 as probably damaging. Under both the autoso-
mal dominant and the autosomal recessive models, a
total of 171 frameshifting shared indels were identi-
fied in the variant calling and filtering process. Since
all of these indels were paired with a wild type allele
(i.e., heterozygous), it is unlikely that any of them
contributed to the clinical phenotype.
Since family members III-29 and IV-18 experi-
enced a very early onset of symptoms, we considered
whether variants in the Apolipoprotein E (APOE)
and nicastrin (NCSTN) genes might have worsened
their clinical phenotype. For APOE, we specifically
inspected the 2, 3 and 4 haplotypes where 4 is
associated with early-onset [20]. Both III-29 and IV-18
are 3/4 heterozygotes. Since carriers of the 4 haplo-
type experience earlier onset than other genotypes, the
combination of PSEN1 variant and one copy of 4 may
explain in the advanced onset in these two patients. We
also searched our whole exome data from patients III-
29 and IV-18 for variants in NCSTN and identified 10
SNVs with known refseq ID numbers, 6 of which were
shared between III-29 and IV-18. However, all of the
shared NCSTN SNVs were located either in introns
or 3’ untranslated regions and none were described as
pathogenic in the NCBI Variant Viewer. No NCSTN
coding variants were found in either patient.
Compassionate use trial with bryostatin
A number of pre-clinical studies have implicated
deficits of PKC in the etiology of AD [14, 21,
22]. Further evidence implicating PKC deficits has
emerged from clinical studies that showed with
autopsy-confirmation that AD patients have signifi-
cant abnormalities in PKC isozymes and PKC-elicited
phosphorylation of downstream substrates [15, 16, 23,
24]. Based on these studies, after the FDA allowed a
compassionate use trial to proceed, patient IV-18 was
treated with the potent PKC epsilon activator, bryo-
statin. The drug (25 micrograms/squared meter) was
administered by intravenous infusion to the patient
over a 1-h period once per week for the first three
weeks of each month. The drug was apparently
well-tolerated with no evidence of hematologic abnor-
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malities or myalgia (the known complications of this
drug which had previously been used clinically in
chemotherapy regimens). More significantly, within
two weeks of trial initiation, patient IV-18 showed
symptomatic improvements. These included vocal-
izations of words, more directed attentional focus,
swallowing, responses to verbal commands, and some
increased range of limb motion. These improve-
ments persisted for approximately 8 weeks, despite
an episode of severe pneumonia that required intu-
bation and hospitalization for 4 weeks. During and
immediately after the episode of pneumonia, bryo-
statin treatment was withheld. These improvements
were consistent with a previous compassionate use trial
for a 95-year-old patient conducted in the Bahamas
with bryostatin 3 years earlier. The current trial was
conducted at intermittent intervals, with interruptions
due to severe respiratory and urinary tract infections,
for 5 months.
DISCUSSION
Through the use of whole exome analysis and dis-
crete filtering, we identified a PSEN1 exon 5 variant
present in two family members with very early onset
dementia. We believe that the Thr147Ile variant is the
primary or sole cause of the disease in our patients for
the following reasons: 1) Polyphen-2 analysis indicates
the variant is probably damaging; 2) The substitution
is located on the helical face of a PS1 transmembrane
domain where all deleterious transmembrane variants
are known to cluster [25]; 3) The same variant was
present in four affected members of three generations
of a French family (ALZ047) with early-onset auto-
somal dominant AD and absent from asymptomatic
ALZ047 members ≥60 years of age [19]; 4) The
variant was present in four affected members of our
family (III-29, IV-1, IV-2, and IV-18); and 5) At least
185 mutations in PSEN1 are known to cause EOAD
[12]. Together, these findings clarify and strengthen
the diagnosis of EOAD in our family.
To our knowledge, the ALZ047 family is the only
prior report of a family with the Thr147Ile substitu-
tion [19]. Our study provides the first description of
the clinical presentation of patients with this variant.
The clinical phenotype of patients with PSEN1 vari-
ants tends to be fairly broad [5]. Our patients shared
features reported in patients with other exon 5 vari-
ants including exhibiting myoclonus, seizures, and
increased muscle tone [3]. However, some members of
the family exhibited novel phenotypes. Affected family
members showed an earlier age of onset than almost all
previously reported cases. Ridge et al. [12] reported a
mean age of onset of cognitive symptoms for persons
with PSEN1 variants as 45.5 years of age, whereas
patient IV-18 was known to have been only 27, and oth-
ers in the pedigree are either documented or believed to
have had symptoms in their late 20 s or very early 30 s.
Patient IV-18 appeared to know what she wanted to
say but could not form her words. This observation
is consistent with expressive aphasia-type symptom
which has not been reported as a clinical feature of AD.
Larner and Doran [3] specifically describe the speech
deficit of only two families. One was described as “ver-
bal perseveration and laconic speech” and one as “a
speech production impairment”, and neither matches
our patient. All other previous reports have been only
of non-specific aphasia.
Age of onset variation between individuals with the
same PSEN1 variant suggests that environmental fac-
tors or other genetic variants may control onset [6, 26].
A single copy of APOE 4 allele sharply increases the
risk of AD [19]. Two reports indicate that the APOE
genotype also influences age of onset in different auto-
somal dominant AD families (PS2 variant Asn141Ile
[27] and PS1 variant Glu280Ala [28]). Patient IV-18
was an 3/4 heterozygote and exhibited symptoms in
her third decade approximately 10–20 years prior to the
ages of onset observed in the ALZ047 family (mem-
bers aged 37–46 at onset). This earlier onset could be
explained by the combined effects of the PSEN1 and
APOE variants.
Since variants in other risk genes could affect the age
of onset, we searched for coding variants in PSEN2,
MAPT, GRN, NCSTN, and PRNP in either III-29 or
IV-18. Patient IV-18 had no coding variants in any of
thesegenes.Onlyonecodingvariant(PRNPrs1799990,
c.385A>G, Met129Val, MAF = 0.26) was identified
in patient III-29. Although Met/Met homozygosity at
PRNP codon 129 is associated with higher risk for
sporadic Creutzfeldt-Jakob disease [29], there is some
conflictoveritseffectinAD.Heetal.reporteddecreased
late-onset risk in Val129 carriers or Val/Val homozy-
gotes but not in early-onset AD [30]. However, the
absence of associations between this variant and late-
onset AD in two recent studies [31, 32] suggest that
rs1799990 is a benign polymorphism.
The clear benefits of the bryostatin therapeutic pro-
tocol during the first eight weeks are consistent with
the benefits observed in a prior compassionate use trial
with bryostatin. While these clinical benefits must be
considered anecdotal—in the absence of age-related
controls—they are worth noting. Considering the very
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advanced stage of a genetically confirmed case of AD,
no other reports to our knowledge have ever shown
comparable benefits.
Our whole exome analysis led to a definitive identifi-
cation of a known AD variant in PSEN1 and confirmed
the diagnosis. Given the continuing decline in cost of
next generation sequencing reagents, automation of
variant calling methods, and potential diagnostic value
susceptibility variants such as APOE4, whole exome
approaches should be considered to be a more com-
prehensive, cost-effective alternative to candidate gene
sequencing for the diagnosis of atypical dementias.
ACKNOWLEDGMENTS
We would like to thank the family members for par-
ticipating in this study, the National Cancer Institute
for its providing bryostatin, Neurotrope BioScience for
its partial support of the drug trial, and the FDA for
allowing the compassionate use trial of bryostatin
for Alzheimer’s disease to proceed under the IND
of the Blanchette Rockefeller Neuroscience Institute
(BRNI). We acknowledge Shana Phares at the BRNI
for her ongoing facilitation of this work, the trial, and
our collaboration, and Megan Justice at Marshall Uni-
versity for assistance in preparing literature citations.
Whole exome sequencing was performed by the
Marshall University Genomics Core Facility which is
supported by the WV-INBRE program and NIH grant
P20GM103434. Acquisition of pedigree construction
software was supported by a grant from the Huntington
Foundation (Huntington, WV).
Authors’ disclosures available online (http://j-alz.
com/manuscript-disclosures/15-0051r1).
SUPPLEMENTARY MATERIAL
The supplementary material is available in the
electronic version of this article: http://dx.doi.org/
10.3233/JAD-150051.
REFERENCES
[1] Kelley BJ, Boeve BF, Josephs KA (2008) Young-onset
dementia: Demographic and etiologic characteristics of 235
patients. Arch Neurol 65, 1502-1508.
[2] Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD
(2010) The diagnosis of young-onset dementia.LancetNeurol
9, 793-806.
[3] Larner AJ, Doran M (2006) Clinical phenotypic heterogene-
ity of Alzheimer’s disease associated with mutations of the
presenilin-l gene. J Neurol 253, 139-158.
[4] Larner AJ, Doran M (2009) Genotype-phenotype relation-
ships of Presenilin-1 mutations in Alzheimer’s disease: An
update. J Alzheimers Dis 17, 259-265.
[5] Larner AJ (2013) Presenilin-1 mutations in Alzheimer’s
disease: An update on genotype-phenotype relationships. J
Alzheimers Dis 37, 653-659.
[6] Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox
NC, Goate A, Frommelt P, Ghetti B, Langbaum JBS, Lopera
F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S,
Reiman EM, Ringman JM, Salloway S, Schofield PR, Sper-
ling R, Tariot PN, Xiong C, Morris JC, Bateman RJ, the
Dominantly Inherited Alzheimer Network (2014) Symptom
onset in autosomal dominant Alzheimer disease: A systematic
review and meta-analysis. Neurology 83, 253-260.
[7] Bertram L, Lill CM, Tanzi RE (2010) The genetics of
Alzheimer disease: Back to the future. Neuron 68, 270-281.
[8] Bettens K, Sleegers K, Van Broeckhoven C (2013) Genetic
insights in Alzheimer’s disease. Lancet Neurol 12, 92-104.
[9] Vilatela MEA, Lopez-Lopez M, Yescas-Gomez P (2012)
Genetics of Alzheimer’s disease. Arch Med Res 43, 622-631.
[10] Guerreiro RJ, Gustafson DR, Hardy J (2012) The genetic
architecture of Alzheimer’s disease: Beyond APP, PSENs and
APOE. Neurobiol Aging 33, 437-456.
[11] Galimberti D, Scarpini E (2012) Genetics of frontotemporal
lobar degeneration. Front Neurol 3, 52.
[12] Ridge PG, Ebbert M, Kauwe J (2013) Genetics of Alzheimer’s
disease. Biomed Res Int 2013, 254954.
[13] Raux G, Guyant-Mare´chal L, Martin C, Bou J, Penet C, Brice
A, Hannequin D, Frebourg T, Campion D (2005) Molecu-
lar diagnosis of autosomal dominant early onset Alzheimer’s
disease: An update. J Med Genet 42, 793-795.
[14] Hongpaisan J, Sun MK, Alkon DL (2011) PKC activa-
tion prevents synaptic loss, A elevation, and cognitive
deficits in Alzheimer’s disease transgenic mice. JNeurosci 31,
630-643.
[15] Khan TK, Alkon DL (2006) An internally controlled periph-
eral biomarker for Alzheimer’s disease: Erk1 and Erk2
responses to the inflammatory signal bradykinin. Proc Natl
Acad Sci U S A 103, 13203-13207.
[16] Khan TK, Alkon DL (2010) Early diagnostic accuracy
and pathophysiologic relevance of an autopsy-confirmed
Alzheimer’s disease peripheral biomarker. Neurobiol Aging
31, 889-900.
[17] Bonner M, Ash S, Grossman M (2010) The new classification
of primary progressive aphasia into semantic, logopenic, or
nonfluent/agrammatic variants. Curr Neurol Neurosci Rep 10,
484-490.
[18] Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasi-
mova A, Bork P, Kondrashov AS, Sunyaev S (2010) Method
and server for predicting damaging missense mutations. Nat
Methods 7, 248-249.
[19] Campion D, Dumanchin C, Hannequin D, Dubois B, Bel-
liard S, Puel M, Thomas-Anterion C, Michon A, Martin C,
Charbonnier F, Raux G, Camuzat A, Penet C, Mesnage V,
Martinez M, Clerget-Darpoux F, Brice A, Frebourg T (1999)
Early-onset autosomal dominant Alzheimer disease: Preva-
lence, genetic heterogeneity, and mutation spectrum. Am J
Hum Genet 65, 664-670.
[20] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE,
Gaskell PC, Small GW, Roses AD, Haines JL, Pericak Vance
AM (1993) Gene dose of apolipoprotein E type 4 allele and
the risk of Alzheimer’s disease in late onset families. Science
261, 921-923.
[21] Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van der
Auwera I, Wera S, Qiao L, Bank B, Nelson TJ, Kozikowski
490 J. Denvir et al. / PSEN1 Variant in a Family with Atypical AD
AP, Van Leuven F, Alkon DL (2004) Therapeutic effects of
PKC activators in Alzheimer’s disease transgenic mice. Proc
Natl Acad Sci U S A 101, 11141-11146.
[22] Hongpaisan J, Xu C, Sen A, Nelson TJ, Alkon DL (2013) PKC
activation during training restores mushroom spine synapses
and memory in the aged rat. Neurobiol Dis 55, 44-62.
[23] Alkon DL, Sun MK, Nelson TJ (2007) PKC signaling deficits:
A mechanistic hypothesis for the origins of Alzheimer’s dis-
ease. Trends Pharmacol Sci 28, 51-60.
[24] KhanTK,NelsonTJ,VermaVA,WenderPA,AlkonDL(2009)
A cellular model of Alzheimer’s disease therapeutic efficacy:
PKC activation reverses A-induced biomarker abnormality
on cultured fibroblasts. Neurobiol Dis 34, 332-339.
[25] Hardy J, Crook R (2001) Presenilin mutations line up along
transmembrane alpha-helices. Neurosci Lett 306, 203-205.
[26] Lopera F, Ardilla A, Martı´nez A, Madrigal L, Arango-Viana
JC, Lemere CA, Arango-Lasprilla JC, Hincapı´e L, Arcos-
Burgos M, Ossa JE, Behrens IM, Norton J, Lendon C, Goate
AM, Ruiz-Linares A, Rosselli M, Kosik KS (1997) Clinical
features of early-onset Alzheimer disease in a large kindred
with an E280A presenilin-1 mutation. JAMA 277, 793-799.
[27] Wijsman EM, Daw EW, Yu X, Steinbart EJ, Nochlin D, Bird
TD, Schellenberg GD (2005) APOE and other loci affect age-
at-onset in Alzheimer’s disease families with PS2 mutation.
Am J Med Genet B Neuropsychiatr Genet 132B 14-20.
[28] Pastor P, Roe CM, Villegas A, Bedoya G, Chakraverty S,
Garcı´a G, Tirado V, Norton J, Rı´os S, Martı´nez M, Kosik KS,
Lopera F, Goate AM (2003) Apolipoprotein E4 modifies
Alzheimer’s disease onset in an E280A PS1 kindred. Ann
Neurol 54, 163-169.
[29] Palmer MS, Dryden AJ, Hughes JT, Collinge J (1991)
Homozygous prion protein genotype predisposes to sporadic
Creutzfeldt-Jakob disease. Nature 352, 340-342.
[30] He J, Li X, Yang J, Huang J, Fu X, Zhang Y, Fan H (2013)
The association between the methionine/valine (M/V) poly-
morphism (rs1799990) in the PRNP gene and the risk of
Alzheimer disease: An update by meta-analysis. J Neurol Sci
326, 89-95.
[31] Sassi C, Guerreiro R, Gibbs R, Ding J, Lupton MK, Troakes
C, Al-Sarraj S, Niblock M, Gallo JM, Adnan J, Killick R,
Brown KS, Medway C, Lord J, Turton J, Bras J; Alzheimer’s
Research UK Consortium, Morgan K, Powell JF, Singleton
A, Hardy J (2014) Investigating the role of rare coding vari-
ability in Mendelian dementia genes (APP, PSEN1, PSEN2,
GRN, MAPT, and PRNP) in late-onset Alzheimer’s disease.
Neurobiol Aging 35, 2881.e1-6.
[32] Smid J1, Landemberger MC, Bahia VS, Martins VR, Nitrini
R (2013) Codon 129 polymorphism of prion protein gene in is
not a risk factor for Alzheimer’s disease. Arq Neuropsiquiatr
71, 423-427.
